UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.

British pharmaceutical group GSK on Friday welcomed victory in drawn out US litigation regarding its Zantac drug for heartburn that allegedly caused cancer. The over-the-counter treatment ...

Shares in GSK fell around 9% this morning after ... of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial. Judge Vivian Medinilla of Delaware Superior Court issued an ...

GSK shares jumped ... claims its Zantac heartburn drug causes cancer. The Delaware Supreme Court said it will review a decision by a lower court to let an upcoming trial hear evidence from ...

Shares in GlaxoSmithKline fell slightly in early trading on Wednesday but stayed above recent lows after the plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial ...

Furthermore, in the first Zantac personal injury case to go to trial, Chicago jurors in late May absolved GSK and Boehringer Ingelheim of fault on claims that Zantac had caused another plaintiff ...

Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical ... In December 2022, approximately 50,000 Zantac cases were dismissed during a pre-trial hearing in Florida.

British pharmaceutical group GSK on Friday (Aug 16) welcomed victory in drawn out US litigation regarding its Zantac drug for heartburn that allegedly caused cancer. The over-the-counter treatment, ...